HighGravityData
Sectors / Biopharma

Biopharma

Its members, what each guided on in its most recent release, and the metrics they have in common. Descriptive only — no composites, no net change, no ranking.
Members
12
Metric families
13

What the group guides on

Guidance series in each metric family, across 12 companies.

Revenue
11
Adjusted EPS
6
GAAP EPS
5
Tax rate
5
Buybacks
5
Gross margin
4
Capex
3
Dividends
3
Adjusted EBITDA
2
Operating margin
2

This season

Each member’s most recent release and how its guidance items moved, newest first.

FiledCompanyHow items moved
Aug 6, 2026BioMarin Pharmaceutical17 New1 Raised1 Narrowed1 Reiterated
Aug 6, 2026Halozyme Therapeutics6 Raised
Aug 5, 2026Eli Lilly2 New2 Raised1 Narrowed1 Reiterated
Aug 4, 2026Amgen3 Raised2 Lowered1 Reiterated
Aug 4, 2026Gilead Sciences11 New3 Raised1 Lowered2 Reiterated
Jul 31, 2026Moderna4 New1 Raised2 Lowered1 Revised4 Reiterated
Jul 30, 2026Neurocrine Biosciences15 New1 Raised
Jul 30, 2026Regeneron Pharmaceuticals2 New8 Raised4 Lowered8 Narrowed
Jul 29, 2026Biogen8 New
Jul 29, 2026Ionis Pharmaceuticals4 New
Jul 28, 2026Incyte8 New1 Raised
Nov 3, 2025Exact Sciences4 New6 Raised
Get this for your own peer set — Peer Guidance Briefing, $3,000.

Members

Every tracked company in the Biopharma sector group.

CompanyTickerLatest release
AmgenAMGNAug 4, 2026
BiogenBIIBJul 29, 2026
BioMarin PharmaceuticalBMRNAug 6, 2026
Eli LillyLLYAug 5, 2026
Exact SciencesEXASNov 3, 2025
Gilead SciencesGILDAug 4, 2026
Halozyme TherapeuticsHALOAug 6, 2026
IncyteINCYJul 28, 2026
Ionis PharmaceuticalsIONSJul 29, 2026
ModernaMRNAJul 31, 2026
Neurocrine BiosciencesNBIXJul 30, 2026
Regeneron PharmaceuticalsREGNJul 30, 2026